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Abnormal telomere maintenance has been significantly implicated in tumor 
development and progression. Telomere length has recently emerged as a promising 
predictor for the risk of various cancers including hepatocellular carcinoma (HCC). 
Nonetheless, the vast majority of these studies measured telomere length in 
hepatocytes and one in peripheral blood lymphocytes with conflicting results. Moreover, 
no studies have been reported on using circulating DNA telomere length as a non-
invasive biomarker of HCC risk. In this nested case-control study, we used real-time 
quantitative PCR to determine the relative telomere length (RTL) in serum DNA samples 
from 140 hepatitis B virus (HBV)-related HCC (HBV-HCC) cases and 280 frequency-
matched cancer-free HBV controls. We found that HBV-HCC cases had a significantly 
longer RTL (median, 0.31; range, 0.02-2.31) versus HBV controls (median, 0.20; range, 
0.01-1.60) (P=0.003). Using the median RTL value in controls as the cutoff point, 
individuals with longer RTLs exhibited a significantly increased risk of HCC compared to 
those with short RTLs in an univariate logistic regression analysis (odds ratio [OR]=1.55, 
95% confidence interval [CI] 1.02-2.33, P=0.038).  However, the strength of this 
association attenuated after multivariate adjustment (OR=1.40, 95% CI 0.90-2.19, 
P=0.132). In a quartile analysis, a significant dose-response relationship was noted in 
the univariate analysis (P trend=0.017) which was attenuated in the multivariate analysis 
(P trend=0.079). Further analyses revealed that the significant association between serum 
RTL and HCC risk was only evident in non-cirrhotic (OR=3.54, 95% CI 1.58-7.93 
P=0.002), but not in cirrhotic (OR=0.95, 95% CI 0.55-1.64, P=0.860) HBV patients. 
Moreover, the significantly increased HCC risk conferred by cirrhosis seemed to be 
modulated by RTL with a significant interaction effect (P for interaction=0.013). 
Collectively, our data suggested that RTL in circulating cell-free serum DNA could 
potentially be used as a novel non-invasive biomarker for non-cirrhotic HCC. Prospective 
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cohort studies are warranted to further validate this finding and assess its clinical 
significance in HCC prevention.  
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INTRODUCTION 
In the United States, the incidence of new acute HBV infection decreased in the 
past two decades, but the number of patients living with chronic HBV infection has been 
growing significantly. This development is partly due to the trend of increasing 
immigration from areas with high HBV endemicity such as Asian and Sub-Arab countries   
[1]. Among the more than 40 million Americans born outside of the United States, about 
1.5 million have chronic HBV infection. Moreover, over 60% of current HBV patients in 
the United States are relatively young and as these patients age, significant increases in 
HBV-induced hepatocellular carcinoma (HCC) and corresponding medical costs are 
expected to occur [1]. Thus, continuous monitoring of these patients and identification of 
high-risk individuals for more targeted and intensive intervention are important to the 
reduction of HBV-induced burden.  
Telomeres consist of small tandem nucleotide repeats (TTAGGG in humans) that 
form the physical ends of eukaryotic chromosomes [2]. The main function of telomeres is 
to stabilize the linear chromosome ends and protect them from degradation and other 
insults resulting from DNA damage response as well as end-to-end fusion [3, 4]. Due to 
the end replication inefficiency of DNA polymerase, telomeres shorten by 50 to 200 base 
pairs within each cell division cycle in normal somatic cells [5]. When the shortening of 
telomeres reaches a critical point, loss of telomere protection will lead to replicative 
senescence and/or apoptosis in normal cells, which in turn prevents tumor initiation 
caused by genomic instability [6, 7].  In addition to the end replication issue, other factors 
such as oxidative stress, chronic inflammation, and loss of telomere binding proteins 
may also contribute to telomere shortening and lead to the tumorigenesis of many solid 
cancers including HCC [8-10]. Furthermore, several studies have demonstrated a 
significant correlation between decreased telomere length of tissue DNAs and promotion 
of hepatocarcinogenesis [11-14].  
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Recently, Liu et al. conducted a case-control study in a Chinese population and 
reported that longer telomeres in peripheral blood leukocytes (PBLs) conferred an 
increased risk of HCC [15]. This finding was consistent with several epidemiologic 
reports indicating a positive correlation between longer telomere length in blood cells 
and a greater susceptibility to breast cancer [16], melanoma [17], and non-Hodgkin 
lymphoma [18], whereas contradictory to the findings of other studies demonstrating that 
shorter telomeres were associated with increased risk in various cancers [19]. In HCC, 
mounting evidence has substantiated the correlation between short telomere length in 
liver tissues and increased cancer risk [20]. These paradox findings regarding telomere 
length in cancer predisposition suggest that the previously observed associations might 
be tissue and/or tumor specific, which warrants further evaluation.  
Biomarkers based on circulating cell-free serum or plasma samples have unique 
advantages over other specimens due to their non-invasive nature, especially in 
prospective studies that have been followed-up for extended time periods but only 
collected serum or plasma samples at the time of study initiation. Circulating serum DNA 
as non-invasive predictive, diagnostic, and prognostic biomarkers has been extensively 
investigated in many cancers [21-23]. In the current study, we sought to evaluate the 
association between serum DNA telomere length and the risk of HBV-related HCC 
(HBV-HCC) using a nested case-control approach in a clinic-based cohort of Korean 
HBV patient population.    
 
MATERIALS AND METHODS 
Study population 
The subjects in this study were selected from an existing and ongoing clinic-
based cohort. The patients were consecutively enrolled from those who visited the Liver 
Disease Prevention Center at Thomas Jefferson University Hospital for treatment of liver 
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diseases, such as chronic HBV or HCV infection, fibrosis, cirrhosis, or HCC. There were 
no restrictions on age, sex, ethnicity, and disease etiology in patient enrollment. 
Enrollment started from 1988 and is still ongoing. As of October 2010, the cohort 
included more than 2600 patients, of which 90% were of Korean ancestry. More than 
90% of the patients in this cohort had HBV infection. To minimize confounding effects 
from disease etiology and ethnicity, we restricted the current study to Korean HBV 
patients. This study has been approved by the Institutional Review Board of Thomas 
Jefferson University.  
Epidemiologic and clinical data collection 
Demographic and clinical data were obtained for each patient through medical 
chart review and consulting with the treating physicians. Demographic variables 
collected in this research included age, sex, ethnicity, smoking status, drinking status, 
cirrhosis, and family history of cancer. An individual who smoked more than 100 
cigarettes in lifetime was defined as an ever smoker, otherwise as a never smoker. 
Never drinkers were defined as those who never consumed alcohol or consumed less 
than or equal to one drink per month. Ever drinkers were those who consumed more 
than one drink per month. Liver cirrhosis and HCC were determined by the combined 
use of clinical diagnosis and imaging studies (ultrasound, computed tomography, or 
magnetic resonance imaging). Blood sample was drawn for each participant for clinical 
laboratory test, and the remaining serum sample was stored at -80 ºC for research 
purpose.  
Measurement of relative telomere length 
Circulating cell-free serum DNA was extracted from 200 µL serum sample using 
QIAamp DNA Blood Mini kit (Qiagen, CA) according to the manufacturer’s protocol. The 
relative telomere length (RTL) of each DNA sample was determined by quantitative real-
time polymerase chain reaction (qRT-PCR) using a protocol described by Cawthon [24], 
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which measured the ratio of the copy number of telomere repeats to the copy number of 
a human single copy gene, 36B4,  with minor modifications. Briefly, the PCR reaction 
(10 µL) for the telomere or 36B4 amplification consisted of 1 X SYBR Green Master Mix 
(Applied Biosystems), 200 nmol/L each telomere or 36B4 specific primers, and 2 µL 
purified serum DNA sample. The thermal cycling conditions for both telomere and 36B4 
were 95 ºC for 10 min followed by 40 cycles of 95 ºC for 15 seconds and 58 ºC for 1 min 
with signal collection. The primer sequences were as follows: forward telomere primer 
(Tel-1), 5’-CGGTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT-3’; reverse 
telomere primer (Tel-2), 5’-GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT-
3’; forward human 36B4 primer, 5’-CAGCAAGTGGGAAGGTGTAATCC-3’; reverse 
human 36B4 primer, 5’-CCCATTCTATCATCAACGGGTACAA-3’. All samples were 
assayed in duplicate on a 0.1 mL fast plate using a StepOnePlus real-time PCR system 
(Applied Biosystems, CA). The same negative controls and calibrator DNAs were 
included on each plate for quality control and calibration of PCR efficiency. A reference 
DNA sample was used to construct a standard curve for RTL measurement on each 
plate. The reference DNA was extracted from 5 ml pooled serum from 25 randomly 
selected patients. For each standard curve, the reference DNA sample was diluted by 
using a 3-fold increment per dilution to produce a seven-point standard curve, between 
40 and 0.05 ng DNA in each reaction. The R2 for each standard curve was ≥ 0.98, with 
acceptable standard deviation set at 0.25 (for the Ct values). If the RTL data for a tested 
sample was found to be out of the acceptable range of the standard curve, the sample 
was repeated.  
Statistical analysis  
All statistical analyses were performed using the SAS software version 9.2 (SAS 
Institute, Cary, NC). The differences in the distribution of host characteristics between 
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cases and controls were compared using the chi-square test for categorical variables, 
and the Student’s t test for continuous variables. Wilcoxon rank-sum test was used to 
evaluate the differences of RTL between cases and controls. RTL was analyzed as 
categorical variable based on a cut-off point at the median, tertile, or quartile value of the 
control group. The association between RTL and HCC risk was estimated using 
unconditional univariate and multivariate logistic regressions to determine the 
unadjusted and adjusted odds ratios (ORs), respectively, and 95% confidence intervals 
(95% CIs). The multivariate analysis controlled for age, sex, smoking status, drinking 
status, cirrhosis, and family history of cancer, where appropriate. The test for interaction 
between demographic factors and RTL on HCC risk was conducted by including a cross-
product term into the logistic regression model.  All statistical tests were two sided, and 
P<0.05 was considered as the threshold of statistical significance.  
 
RESULTS 
Demographic characteristics of the study subjects  
The distributions of patient characteristics were summarized in Table 1. This 
study included 140 HBV-HCC cases and 280 cancer-free HBV controls that were 1:2 
frequency-matched to cases on age and gender. All participants were restricted to 
Korean HBV patients to control the confounding effect of ethnicity and HCC etiology. As 
shown in Table 1, there was no significant differences between cases and controls on 
age (mean ± standard deviation [SD], 55.3 ± 8.8 years vs. 53.7 ± 9.6 years, respectively, 
P=0.099) and gender (P=0.327). No significant differences were identified between 
cases and controls with regard to smoking status (P=0.096) and drinking status 
(P=0.334). As expectedly, a significant higher percentage of cirrhotic patients were 
identified in HCC cases (75.0%) versus controls (41.4%) (P<0.001). Additionally, there 
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was a significantly higher percentage of patients with a family history of cancer among 
cases (47.9%) than controls (32.9%) (P=0.003).  
The distribution of RTL in cases and controls by host characteristics 
As shown in Table 2, the overall serum DNA RTL was significantly longer in HCC 
cases than in cancer-free HBV controls [median, 0.31 (range, 0.02-2.31) vs. median, 
0.20 (range, 0.01-1.60), P=0.003]. We further conducted a stratified analysis to evaluate 
the RTL distribution differences between cases and controls by host characteristics. The 
differences of RTL between cases and controls remained at least borderline significant 
in patients regardless of age, smoking status, and drinking status. In comparison, the 
difference was only evident in males (P=0.001) but not females (P=0.757), in non-
cirrhotic patients (P=0.007) but not cirrhotic patients (P=0.423), and in patients without a 
family history of cancer (P=0.002) but not in those with a family history of cancer 
(P=0.264). Moreover, we also compared the RTL differences between the strata of each 
variable in cases and controls separately, and identified a significant difference between 
cirrhotic and non-cirrhotic HBV controls. The median (range) of RTL was 0.28 (0.01-
1.60) and 0.18 (0.01-1.11) in cirrhotic and non-cirrhotic HBV controls, respectively 
(P=0.004) (Table 2). 
RTL and HCC risk 
We estimated the association between serum DNA RTL and the risk on HCC by 
univariate and multivariate logistic regression analyses, through treating RTL as a 
categorical variable based on a cut off value of median, tertile or quartile distribution in 
cancer-free HBV controls. As shown in Table 3, individuals with longer RTL by median 
cut-off had a significantly increased risk of HCC in univariate analysis (unadjusted 
OR=1.55, 95% CI, 1.02-2.33, P=0.038), but not in multivariate analysis after adjusting all 
host variables including age, gender, smoking status, drinking status, cirrhosis, and 
family history of cancer (adjusted OR=1.40, 95% CI 0.90-2.19, P=0.132). When patients 
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were further categorized according to the tertile or quartile distribution of RTL values in 
controls, we found that, using the first (shortest RTL) group as reference, there was a 
significant dose-response relationship between longer RTL and increased HCC risk in 
the univariate analysis (P
 trend=0.013 by tertile; P trend=0.017 by quartile), which was 
attenuated in the multivariate analysis (P
 trend=0.067 by tertile; P trend=0.079 by quartile). 
The OR for the second or third group in the tertile analysis was 1.15 (95% CI 0.67-1.96, 
P=0.615) and 1.85 (95% CI 1.12-3.06, P=0.017), respectively in the univariate analysis, 
and 1.18 (95% CI 0.67-2.08, P=0.577) and 1.64 (95% CI 0.96-2.82, P=0.072), 
respectively in the multivariate analysis. Similar results were obtained in the quartile 
analysis (Table 3). Because we suspected that the attenuated association between RTL 
and HCC risk was due to a strong confounding from cirrhosis, we conducted another 
multivariate analysis adjusting all other host variables but not cirrhosis. The result of this 
analysis was similar to that of the univariate analysis: individuals with longer TRL by 
median cut-off had a significantly increased HCC risk (OR=1.59; 95% CI 1.04-2.42, 
P=0.031) and a significant dose-response effect was observed between longer RTL and 
increased HCC risk in the tertile and quartile analysis (P trend =0.007 and 0.012, 
respectively). The results of similar multivariate analysis without adjusting other host 
characteristics including age, gender, smoking status, drinking status, and family history 
of cancer yielded similar results to that of the multivariate analysis adjusting all the 
variables (data not shown). 
The association of RTL with HCC risk stratified by host characteristics 
To further address the apparent attenuation of the significance of the observed 
association in the multivariate analysis, we conducted a stratified analysis to evaluate 
the potential modulating effect on the association between RTL and HCC risk by host 
variables. Consistent with the results of Tables 2 and 3, we found a significant 
association between long RTL and increased HCC risk that was observed only in non-
 12 
cirrhotic HBV patients (adjusted OR=3.54, 95%CI 1.58-7.93, P=0.002), but not in 
cirrhotic HBV patients (adjusted OR=0.95, 95% CI 0.55-1.64, P=0.860) (Table 4). A 
significant association was also observed in never drinkers (adjusted OR=1.93, 95%CI 
1.04-3.60, P=0.038). In addition, borderline significant associations were observed in 
males (P=0.076), and patients without a family history of cancer (P=0.078) (Table 4).  
Association between cirrhosis and HCC risk modulated by serum DNA RTL 
Because longer RTL conferred a significantly increased risk of HCC in non-
cirrhotic but not in cirrhotic patients, we sought to evaluate whether the effect of cirrhosis 
on HCC risk was also modulated by RTL. As shown in Table 5, as expected, cirrhosis 
was significantly associated with an increased HCC risk (adjusted OR=4.11, 95% CI 
2.60-6.51, P=1.48 x 10-9). This effect was much more prominent in patients with short 
RTL (adjusted OR=8.04, 95% CI 3.82-16.90, P=3.89 x 10-8), compared to those with 
long RTL (adjusted OR=2.35, 95% CI 1.27-4.33, P=0.006). Moreover, we observed a 
statistically significant interaction effect between cirrhosis and RTL on the prediction of 
the risk of HBV-HCC (P for interaction=0.013). 
 
DISCUSSION  
In the current study, we evaluated the association between RTL in circulating 
cell-free serum DNA and the risk of HBV-related HCC in a clinic-based patient 
population. We found that longer RTL was associated with an increased risk on HBV-
HCC, an effect that was much more evident in patients without cirrhosis than those with 
cirrhosis. Further analysis revealed a significant interaction effect between RTL and 
cirrhosis in the modulation of HCC risk in HBV patients.   
The use of telomere length as a potential predictor for cancer risk and prognosis 
has been extensively investigated during the past decade. The vast majority of these 
studies have been focused on evaluating telomere length in tumor tissues, whereas 
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increasing studies were conducted recently assessing this relationship through 
measuring telomere length in PBLs using qRT-PCR [24, 25]. In HCC, many studies that 
measured telomere length in tumor and surrounding normal tissue with mixed results. 
The majority of these studies reported that telomere shortening was involved in 
hepatocarcinogenesis, whereas there were also some studies showing that longer 
telomeres contribute to increased HCC risks [11-13, 20, 26-28]. In addition to these 
discrepant findings, these studies were focused mainly on the liver tissues, which reflect 
more on the primary tumor characteristics than on the genetic background of the 
patients. Recently, Liu et al. measured RTL in PBLs in a Chinese population, and found 
that longer RTL was significantly associated with an increased risk of HBV-HCC, 
comparing to both healthy controls and cancer-free controls with chronic liver diseases 
such as cirrhosis or fibrosis [15]. As a surrogate specimen for individual’s genetic 
background, PBL has been widely used in epidemiological studies. However, the use of 
PBL as non-invasive biomarker has been limited, although they carry considerable 
clinical value, especially in those prospective cohort studies with several decades’ 
clinical follow-up that only collected serum or plasma samples at the time of study 
initiation. To the best of our knowledge, there has not been a population-based study 
determining the association of serum DNA telomere length with cancer risk or clinical 
outcome. In the current study, we measured the RTL in circulating cell-free serum DNA 
in a Korean American HBV-infected population, and observed a significant correlation 
between long RTL and increased risk of HBV-HCC. This finding is consistent with the 
results of the study of Liu et al [15]. The overall median value of RTL in our study was 
lower than that of Liu et al., which is possibly accounted for by the difference between 
circulating cell-free DNA and PBL DNA. Circulating cell-free DNA is a heterogeneous 
mixture including DNA released from various sources with broad variations in contents 
and concentrations. It consists of DNA from a wide spectrum of cells such as necrotic 
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and apoptotic cells, active blood cells, and circulating tumor cells in cancer patients [22], 
In comparison,  the DNA from PBLs is highly homogeneous and to a larger extent 
reflects the constitutional genetic background of the subjects.  
Cirrhosis is a major risk factor for HCC and between 60-90% of patients with 
primary HCC have underlying cirrhosis [29-31]. In our study, the increased HCC risk 
conferred by long serum DNA RTL was only evident in non-cirrhotic patients. This could 
be due to the possibility that the strong effect of cirrhosis on HCC might have 
overshadowed the association conferred by long telomere length in our study population. 
Alternatively, there may be different molecular mechanisms underlying the development 
of HCC with and without cirrhosis. For instance, HBV viral genome can directly integrate 
into the host human genome and act as an oncogenic factor, a process that is 
independent of the chronic inflammation that commonly characterizes cirrhosis [32]. In 
line with this notion, recent in vitro and in vivo studies suggested that the HBx protein, 
encoded by the HBV viral genome, increases both the expression of telomere reverse 
transcriptase and telomerase activities, the enzyme responsible for the maintenance of 
telomere length, thus prolonging the lifespan of hepatocytes and contributing to 
malignant transformation [33, 34]. Partly due to these properties of HBV genome, liver 
cirrhosis in patients with chronic HBV infection is only present in about 60-70% of HBV-
HCC cases and not a prerequisite step for tumorigenesis [35]. These lines of evidence 
are consistent with our data linking telomere length and the risk of non-cirrhotic HBV-
HCC. However, the molecular mechanism underlying these observations still needs 
further investigations.  
Mixed findings have been identified from the numerous studies that have 
extensively investigated the relationship between altered telomere length and cancer 
risk. Wentzensen et al. conducted a meta-analysis and found that long telomere length 
was associated with the increased risk of breast cancer, lung cancer, colorectal cancer, 
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and Non-Hodgkin’s lymphoma, but reduced risk of bladder cancer, esophageal cancer, 
gastric cancer, head and neck cancer, ovarian cancer, and renal cell carcinoma [19]. In 
HCC, our finding was consistent with the study of Liu et al., who conducted a case-
control analysis in a Chinese population and reported that HCC patients had significantly 
longer RTL measured using DNA samples of peripheral blood leukocytes, compared to 
both liver disease-free normal controls and controls with chronic liver diseases such as 
chronic HBV infection and liver cirrhosis [15]. However, the findings are contradictory to 
several previous studies reporting that cancerous liver tissues had a shorter telomere 
length compared to paired normal tissues or non-cancerous liver tissues [14, 27, 36, 37]. 
Several potential reasons may account for these discrepancies. Ours and Liu’s studies 
were conducted in Asians whereas almost all other studies used Caucasian subjects. It 
has been demonstrated there were significant racial differences in the distribution of 
telomere length [38-40]. Whether these differences have an impact on the role of 
telomere length in the progression of HBV-HCC remains a task of evaluation. Moreover, 
our study used circulating cell-free DNA from serum samples and Liu’ study used PBLs, 
whereas the majority of other studies used hepatocytes [14, 27, 36, 37]. The RTL 
measurement in hepatocytes from liver tissue was more likely a reflection of the 
characteristics of telomere homeostasis, rather than a simple constitutive non-invasive 
biomarker of risk prediction measured from leukocytes or serum [15]. Consistent with 
this notion and the results of our study, Wiemann et al. reported that in cirrhotic patients, 
telomere shortening was mainly restricted to hepatocytes of cirrhotic liver tissues 
whereas lymphocytes and satellite cells in areas of cirrhosis had significantly longer 
telomere length [14]. Furthermore, telomere dysfunction has been reported to have dual 
roles in liver carcinogenesis. Short telomere shortening appears to have a tumor-
initiating effect through inducing chromosomal instability [27, 41]. In comparison, the 
elongation of telomeres by the activation of telomerase has also been reported to 
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contribute to tumor growth and progression [20]. Various independent studies have 
demonstrated a significantly elevated activity of telomerase at the stage of severe liver 
diseases such as cirrhosis and HCC [42-44], which is consistent with the findings of our 
and Liu’s studies that telomere length increases along with liver disease progression. 
Collectively, these lines of evidence indicate the requirement of a balanced state of 
telomere length in the normal physiological liver functions, since either extremely short 
or long telomeres leads to liver pathogenesis. Additional biomarker and basic studies are 
needed to further explain these paradoxical findings and reveal the underlying 
mechanisms. 
The modulating effect of telomere length by environmental factors such as 
cigarette smoking and alcohol use have been reported in HBV-HCC [15], and some 
other solid tumors [45, 46]. In our study, we only observed a borderline significant 
association between an increased HCC risk with long serum RTL among never drinkers 
but not ever drinkers (Table 4). In addition, no significant interaction effect was identified 
between RTL and smoking or drinking status (data not shown). These results may likely 
be explained by the adequate matching between cases and controls on smoking and 
drinking status. Moreover, due to the limitation of the retrospective clinic-based study, 
we did not have detailed data of the intensities of smoking and drinking which could also 
contribute to the paradox findings. Further larger prospectively designed cohort studies 
are warranted to test the cumulative and interactions effects between RTL and these 
environmental exposures on the risk of HCC. 
A major strength of this study is the unique and highly homogenous HBV patient 
population. Our study is restricted to Korean American HBV patients only, eliminating the 
confounding effects of ethnicity and disease etiology. The vast majority of patients were 
infected with HBV at birth or childhood, making this population an ideal resource to study 
the long-term outcome of HBV infection at the population level. Strict matching criteria 
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were implemented between cases and controls to minimize the potential confounding 
effects from other major risk factors. To the best of our knowledge, this is the first study 
to demonstrate that RTL in circulating cell-free serum DNA could potentially be used as 
a simple inexpensive and non-invasive biomarker of HCC risk and the findings are highly 
consistent with that obtained using PBLs [15]. This proof-of-concept finding makes 
serum a valuable resource for RTL-based biomarker research, especially in prospective 
longitudinal studies that have been followed-up for extended time periods but only 
collected serum samples at the time of study initiation. 
There are also limitations in this study. First, because of the heterogeneous 
nature of circulating serum DNA, the mechanism underlying the significant associations 
observed in this study remains a task for further evaluation. Second, due to the nature of 
retrospective case-control design, our study also has the reverse-causation limitation 
that is inherent in most case-control studies, and may not differentiate the causal 
relationship between RTL alteration and HCC development. Prospective and longitudinal 
studies are needed to address this issue. 
In conclusion, our study reported for the first time that longer RTL in circulating 
cell-free serum DNA was significantly associated with an increased risk of non-cirrhotic 
HBV-HCC, a finding that warrants further retrospective and prospective validations, in-
depth molecular characterizations, and assessments to determine the clinical value in 
the risk prediction and diagnosis of HCC. 
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Table 1. Distribution of host characteristics in all cases and controls 
Variable HCC Cases ( n=140) HBV controls (n=280) P value 
Age: Mean ± SD 55.3 ±  8.8 53.7 ±  9.6 0.099 
Gender     
    Female  22(15.7)  55(19.6)  
    Male 118(84.3) 225(80.4) 0.327 
Smoking status    
    Never  69(49.3) 162(57.9)  
    Ever  71(50.7) 118(42.1) 0.096 
Drinking status      
    Never  67(47.9) 148(52.9)  
    Ever  73(52.1) 132(47.1) 0.334 
Cirrhosis    
    No  35(25.0) 164(58.6)  
    Yes 105(75.0) 116(41.4) < 0.001 
Family cancer     
    No  73(52.1) 188(67.1)  
    Yes  67(47.9)  92(32.9) 0.003 
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Table 2. RTL distribution by host characteristics in cases and controls 
RTL: Median (Range) Variable 
HCC cases (n=140) HBV controls (n=280) P value 
Overall  0.31(0.02-2.31) 0.20(0.01-1.60) 0.003 
Age, y     
 ≤ 54.1 0.32(0.02-2.22) 0.22(0.02-1.15) 0.071 
 > 54.1 0.30(0.02-2.31) 0.18(0.01-1.60) 0.016 
 
P value 0.998 0.414  
Gender     
 Female 0.28(0.02-2.22) 0.26(0.01-1.60) 0.757 
 Male 0.32(0.02-2.31) 0.19(0.01-1.15) 0.001 
 
P value 0.866 0.102  
Smoking status    
 Never 0.29(0.02-2.30) 0.20(0.01-1.60) 0.045 
 Ever 0.32(0.02-2.31) 0.21(0.02-1.15) 0.021 
 
P value 0.997 0.674  
Drinking status    
 Never 0.28(0.02-2.21) 0.20(0.01-1.60) 0.077 
 Ever 0.34(0.02-2.31) 0.22(0.02-1.15) 0.011 
 
P value 0.611 0.912  
Cirrhosis     
 No 0.29(0.02-2.21) 0.18(0.01-1.11) 0.007 
 Yes 0.33(0.02-2.31) 0.28(0.01-1.60) 0.423 
 
P value 0.904 0.004  
Family Cancer    
 No 0.34(0.02-2.30) 0.20(0.01-1.60) 0.002 
 Yes 0.27(0.02-2.31) 0.20(0.01-1.35) 0.264 
 
P value 0.120 0.947  
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Table 3. HCC risk as estimated by telomere length on HBV controls 
Unadjusted  Multivariate-adjusted1  Multivariate-adjusted2 RTL HCC cases HBV controls 
OR (95%CI)  P Value   OR (95%CI) P Value   OR (95%CI) P Value 
By median           
    Short 55 140 1.00   1.00   1.00  
    Long 85 140 1.55(1.02-2.33) 0.038  1.40(0.90-2.19) 0.132  1.59(1.04-2.42) 0.031 
By tertile           
    First tertile 35 93 1.00   1.00   1.00  
    Second tertile 41 95 1.15(0.67-1.96) 0.615  1.18(0.67-2.08) 0.577  1.16(0.68-2.01) 0.583 
    Third tertile 64 92 1.85(1.12-3.06) 0.017  1.64(0.96-2.82) 0.072  1.99(1.18-3.32) 0.009 
    P trend 
  
 0.013 
  0.067   0.007 
By quartile           
    First quartile 26 70 1.00   1.00   1.00  
    Second quartile 29 70 1.12(0.60-2.08) 0.732  1.26(0.65-2.46) 0.492  1.15(0.61-2.17) 0.665 
    Third quartile 35 70 1.35(0.73-2.47) 0.336  1.43(0.75-2.72) 0.283  1.37(0.74-2.54) 0.316 
    Fourth quartile 50 70 1.92(1.08-3.43) 0.027  1.72(0.93-3.19) 0.085  2.06(1.14-3.72) 0.017 
    P trend 
    
  0.017 
    0.079     0.012 
Notes: 1Adjusted for age, gender, smoking status, drinking status, cirrhosis and family history of cancer. 2Adjusted for age, gender, smoking status, 




Table 4. HCC risk estimated by RTL on HBV controls stratified by host characteristics 
Variable RTL (by median in 




Age, y      
    ≤ 53.1 Short 27 77 1.00  
 Long 35 72 1.21( 0.63- 2.32) 0.574 
    > 53.1 Short 31 75 1.00  
 Long 47 56 1.64( 0.88- 3.04) 0.120 
Gender      
   Female Short 10 27 1.00  
 Long 12 28 0.96( 0.30- 3.07) 0.939 
    Male Short 48 125 1.00  
 Long 70 100 1.55( 0.96- 2.52) 0.076 
Smoking status     
    Never Short 29 88 1.00  
 Long 40 74 1.49( 0.81- 2.76) 0.200 
    Ever Short 29 64 1.00  
 Long 42 54 1.40( 0.73- 2.70) 0.312 
Drinking status     
    Never Short 28 84 1.00  
 Long 39 64 1.93( 1.04- 3.60) 0.038 
    Ever Short 30 68 1.00  
 Long 43 64 1.06( 0.55- 2.06) 0.857 
Cirrhosis      
    No Short 12 101 1.00  
 Long 23 63 3.54( 1.58- 7.93) 0.002 
    Yes Short 46 51 1.00  
 Long 59 65 0.95( 0.55- 1.64) 0.860 
Family cancer     
    No Short 28 101 1.00  
 Long 45 87 1.71( 0.94- 3.09) 0.078 
    Yes Short 30 51 1.00  
 Long 37 41 1.21( 0.61- 2.38) 0.587 
Note: 1Adjusted for age, gender, smoking status, drinking status, cirrhosis and family history of 
cancer, where appropriate.  
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Table 5.  Association of cirrhosis with the risk of HBV-HCC modulated by RTL  
cirrhosis and RTL HCC cases HBV controls OR (95%CI) 1 P value 
In all patients     
    Non-cirrhosis 35 164 1.00  
    cirrhosis 105 116 4.11(2.60-6.51) 1.48 x 10-9 
     
In patients with short RTL     
    Non-cirrhosis 12 101 1.00  
    cirrhosis 46 51 8.04 (3.82-16.90) 3.89 x 10-8 
     
In patients with long RTL     
    Non-cirrhosis 23 63 1.00  
    cirrhosis 59 65 2.35(1.27-4.33) 0.006 
    P interaction       0.013 
Note: 1Adjusted for age, gender, smoking status, drinking status, and family history of cancer. 
 
